Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Collegium Pharma (COLL)

Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Collegium Pharma 100 Technology Center Drive Stoughton MA 02072 USA

www.collegiumpharma.com Employees: 197 P: 781-713-3699 F: 781-828-4697

Description:

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States.

Key Statistics

Overview:

Market Capitalization, $K 1,054,042
Enterprise Value, $K 1,220,132
Shares Outstanding, K 32,214
Annual Sales, $ 566,770 K
Annual Net Income, $ 48,160 K
Last Quarter Sales, $ 145,280 K
Last Quarter Net Income, $ 19,610 K
EBIT, $ 203,640 K
EBITDA, $ 351,660 K
60-Month Beta 0.95
% of Insider Shareholders 3.98%
Float, K 30,932
% Float 96.02%
Short Volume Ratio 0.60

Growth:

1-Year Return 49.23%
3-Year Return 67.97%
5-Year Return 80.62%
5-Year Revenue Growth 102.12%
5-Year Earnings Growth 519.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.62 on 08/08/24
Next Earnings Date 11/07/24 [AMC]
Earnings Per Share ttm 5.41
EPS Growth vs. Prev Qtr 8.33%
EPS Growth vs. Prev Year 26.55%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

COLL Ratios

Ratio
Price/Earnings ttm 6.18
Price/Earnings forward 5.76
Price/Earnings to Growth N/A
Return-on-Equity % 107.62%
Return-on-Assets % 19.49%
Profit Margin % 8.50%
Debt/Equity 1.46
Price/Sales 1.90
Price/Cash Flow 3.11
Price/Book 5.05
Book Value/Share 6.62
Interest Coverage -1.91
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar